For thyroid cancer, stemness markers such as CD133, ALDH‐1, OCT‐4, and Nanog are widely used to evaluate tumor stemness, with CD133 being the most recognized as a cell membrane marker.[29] Through the application of the above‐mentioned stemness markers for stemness scoring on these eight cell clusters, we identified a subgroup of cells with markedly elevated stemness (Figure S1B, Supporting Information). The gene discussed is NANOG; the disease is neoplasm.